Jason Butler
Stock Analyst at Citizens
(4.70)
# 172
Out of 5,238 analysts
142
Total ratings
53.1%
Success rate
49.17%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTX Avalo Therapeutics | Initiates: Market Outperform | $52 | $21.57 | +141.08% | 1 | Apr 6, 2026 | |
| CYTK Cytokinetics | Maintains: Market Outperform | $88 → $96 | $76.91 | +24.82% | 18 | Feb 25, 2026 | |
| IRWD Ironwood Pharmaceuticals | Upgrades: Market Outperform | $8 | $4.22 | +89.57% | 2 | Jan 5, 2026 | |
| NSRX Nasus Pharma | Initiates: Market Outperform | $19 | $3.15 | +503.17% | 1 | Dec 18, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Market Outperform | $114 → $131 | $122.74 | +6.73% | 5 | Dec 16, 2025 | |
| PRTA Prothena Corporation | Maintains: Market Outperform | $11 → $19 | $10.73 | +77.07% | 12 | Dec 1, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Market Outperform | $91 → $92 | $64.12 | +43.48% | 14 | Nov 4, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Market Outperform | $9 → $12 | $4.32 | +177.78% | 8 | Oct 9, 2025 | |
| RAPP Rapport Therapeutics | Reiterates: Market Outperform | $28 | $38.04 | -26.39% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $22.40 | +65.18% | 15 | Jun 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $39 | $21.42 | +82.07% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $6 | $4.21 | +42.52% | 11 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $115 → $100 | $23.08 | +333.28% | 1 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $42 → $38 | $16.61 | +128.78% | 8 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $17 → $18 | $11.13 | +61.73% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $3.14 | +27.39% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $782.17 | -10.38% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $3.21 | +180.37% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $7.92 | +139.90% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $5.92 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $5.93 | +708,163.07% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $15.34 | +656.19% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $4.34 | +107.37% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.80 | - | 1 | Dec 2, 2020 |
Avalo Therapeutics
Apr 6, 2026
Initiates: Market Outperform
Price Target: $52
Current: $21.57
Upside: +141.08%
Cytokinetics
Feb 25, 2026
Maintains: Market Outperform
Price Target: $88 → $96
Current: $76.91
Upside: +24.82%
Ironwood Pharmaceuticals
Jan 5, 2026
Upgrades: Market Outperform
Price Target: $8
Current: $4.22
Upside: +89.57%
Nasus Pharma
Dec 18, 2025
Initiates: Market Outperform
Price Target: $19
Current: $3.15
Upside: +503.17%
ABIVAX Société Anonyme
Dec 16, 2025
Maintains: Market Outperform
Price Target: $114 → $131
Current: $122.74
Upside: +6.73%
Prothena Corporation
Dec 1, 2025
Maintains: Market Outperform
Price Target: $11 → $19
Current: $10.73
Upside: +77.07%
Halozyme Therapeutics
Nov 4, 2025
Maintains: Market Outperform
Price Target: $91 → $92
Current: $64.12
Upside: +43.48%
Aquestive Therapeutics
Oct 9, 2025
Maintains: Market Outperform
Price Target: $9 → $12
Current: $4.32
Upside: +177.78%
Rapport Therapeutics
Jul 8, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $38.04
Upside: -26.39%
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $22.40
Upside: +65.18%
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $21.42
Upside: +82.07%
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $4.21
Upside: +42.52%
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $23.08
Upside: +333.28%
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $16.61
Upside: +128.78%
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $11.13
Upside: +61.73%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $3.14
Upside: +27.39%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $782.17
Upside: -10.38%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $3.21
Upside: +180.37%
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $7.92
Upside: +139.90%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $5.92
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $5.93
Upside: +708,163.07%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $15.34
Upside: +656.19%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $4.34
Upside: +107.37%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $2.80
Upside: -